Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

VistaGen Receives $5 Million Upfront Fee from EverInsight for SAD Therapy

publication date: Aug 5, 2020

VistaGen of South San Francisco announced that Shanghai's EverInsight completed payment of a $5 million license fee for rights to its novel treatment for social anxiety disorder (SAD) in China and other Asian countries. EverInsight will be responsible for Asia development of PH94B, a rapid-onset neuroactive nasal spray. The $5 million upfront payment was part of a $177 million package agreed to by the companies that also included milestone payments, plus royalties. ChinaBio® advised VistaGen on the transaction. More details....

Stock Symbol: (NSDQ: VTGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.